Clinical trial • Phase III • Oncology|Ophthalmology
Nivolumab for Uveal melanoma
Phase III trial of Nivolumab for Uveal melanoma. 15 participants.
Overview
- Trial Therapeutic Area
- Oncology|Ophthalmology
- Trial Disease
- Uveal melanoma
- Trial Stage
- Phase III
- Drug Modality
- Monoclonal antibody
Key dates
- Initial CTIS Submission Date
- 17-12-2025
- First CTIS Authorization Date
- 04-02-2026
Trial design
Phase III trial across 1 site in Denmark.
- Target Sample Size
- 15
Recruitment
- Planned Sample Size
- 15
- Recruitment Window Months
- 36
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 15
Denmark
- Earliest CTIS Part Ii Submission Date
- 03-02-2026
- Latest Decision Or Authorization Date
- 04-02-2026
- Processing Time Days
- 1
- Number Of Sites
- 1
- Number Of Participants
- 15
Sites
- Site Name
- Herlev Hospital
- Department Name
- Department of Oncology, Herlev Hospital, Denmark
- Principal Investigator Name
- Inge Marie Svane
- Principal Investigator Email
- inge.marie.svane@regionh.dk
- Contact Person Name
- Inge Marie Svane
- Contact Person Email
- inge.marie.svane@regionh.dk
- Number Of Participants
- 15
Sponsor
Primary sponsor
- Full Name
- Region Hovedstaden
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Denmark
Investigational products
- Investigational Product Name
- Nivolumab
- Active Substance
- Nivolumab
- Modality
- Monoclonal antibody
- Investigational Product Name
- Ipilimumab
- Active Substance
- Ipilimumab
- Modality
- Monoclonal antibody
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.